Magarotto Valeria, Salvini Marco, Bonello Francesca, Bringhen Sara, Palumbo Antonio
a Myeloma Unit, Division of Hematology , University of Torino , Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino , Torino , Italy.
Leuk Lymphoma. 2016;57(3):537-56. doi: 10.3109/10428194.2015.1102245. Epub 2015 Dec 23.
Novel agents, such as immunomodulantory drugs (IMiDs) and proteasome inhibitors (PI), have significantly improved overall survival of multiple myeloma (MM) patients. Yet, MM remains an incurable disease, relapse inevitably occurs and patients tend to become resistant to subsequent treatments. This led to the evaluation of new treatment strategies. The recent development of monoclonal antibodies is changing the treatment algorithm of MM by increasing the therapeutic armamentarium. Elotuzumab and Daratumumab were shown to be very effective and are likely to be soon approved by the FDA. Other antibodies are in pre-clinical or early clinical phases of evaluation and further investigation and more robust data are needed. This review will give an overview of the most active monoclonal antibodies against MM.
新型药物，如免疫调节药物（IMiDs）和蛋白酶体抑制剂（PI），显著提高了多发性骨髓瘤（MM）患者的总生存率。然而，MM仍然是一种无法治愈的疾病，不可避免地会复发，并且患者往往会对后续治疗产生耐药性。这促使人们评估新的治疗策略。单克隆抗体的最新进展通过增加治疗手段正在改变MM的治疗方案。埃罗妥珠单抗和达雷妥尤单抗已显示出非常有效，并且很可能很快获得美国食品药品监督管理局（FDA）的批准。其他抗体正处于临床前或早期临床评估阶段，还需要进一步研究和更有力的数据。本综述将概述针对MM最具活性的单克隆抗体。
